HALO News and Press, Halozyme Therapeutics Inc. From 05/22/19

At its R&D Day today, argenx ( ARGX +0.5% ) will present data on two new pipeline candidates: ARGX-117, a next-generation complement-targeting antibody against C2 and ARGX-118, an antibody targeting a protein called Galectin-10 that plays a key role in severe asthma, in-licensed from B...

Halozyme (NASDAQ: HALO ) announces that argenx has selected a second target under ENHANZE Technology collaboration and license agreement announced in February 2019. More news on: Halozyme Therapeutics, Inc., Healthcare stocks news, Read more ...

SAN DIEGO , May 22, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has selected a second target under the collaboration and license agreement the companies announce...

SAN DIEGO , May 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the Bank of America Merrill Lynch Health Care Conference 2019 in Las Vegas, NV. Laurie Stelzer , ...

Halozyme Therapeutics, Inc. (HALO) Q1 2019 Earnings Conference Call May 07, 2019, 16:30 ET Company Participants Albert Kildani - VP, IR & Corporate Communications Laurie Stelzer - SVP & CFO Helen Torley - President, CEO & Director Dimitrios Chondros - Chief Medical ...

Halozyme Therapeutics (NASDAQ: HALO ): Q1 GAAP EPS of $0.01 misses by $0.03 . Revenue of $56.9M (+84.3% Y/Y) misses by $10.9M . Press Release More news on: Halozyme Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

SAN DIEGO , May 7, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the first quarter ended March 31, 2019 and provided an update on recent corporate...

Halozyme Therapeutics (NASDAQ: HALO ) is scheduled to announce Q1 earnings results on Tuesday, May 7th, after market close. More news on: Halozyme Therapeutics, Inc., Earnings news and commentary, , Healthcare stocks news, Read more ...

ACLS , ADT , APEI , ATO , ATSG , AVD , AVLR , BECN , BOLD , CERS , CHUY , COLD , CRAY , CRZO , CSOD , CTRE , CWK , DDD , DIOD , DVA , EA , EDIT , ENTA , ESE , EVH , EVRI , FANG , FARM , FATE , FG , FLT , FTSI , GHDX , GTES , HALO , HCLP , HUBS , ICHR , ...

SAN DIEGO , May 6, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of biotechnology and pharmaceutical industry expert Alison A. Armour , M.B. Ch.B., B....